Importantly, we showed that disruption to FA pathway function was able to render glioma cells sensitive to temozolomide irrespective of MGMT status/expression levels [150], demonstrating a potential large scope for such an approach within the clinical setting. This evidence concerns the gene MGMT and glioma.